Tarsus to Participate in Upcoming Investor Conferences
Tarsus (NASDAQ:TARS) announced that management will attend two investor events: the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, and the H.C.
Rhea-AI Summary
Tarsus (NASDAQ:TARS) announced that management will attend two investor events: the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, and the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, which will include a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET. Live webcasts, replays, and additional details will be available in the events section of the Tarsus website, with replays posted within 48 hours and archived for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction – TARS
In the Sep 2 session, TARS gained 11.80%, reflecting a significant positive market reaction. Argus tracked a peak move of +21.9% during that session. Our momentum scanner triggered 78 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th
- H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15th, where management plans to participate in a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET.
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com